Although there are interesting findings, this study still has some limitations:(1) More clinical data are needed to validate the prognostic impact of PRR11 in bladder cancer; (2) There is also a need to explore whether PRR11 promotes bladder cancer progression through other mechanisms; (3) Potential drugs targeting PRR11 in bladder cancer must be investigated. This evidence concerns the gene PRR11 and urinary bladder carcinoma.